These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36862364)

  • 1. Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary.
    Kolbinger FR; Bernard V; Lee JJ; Stephens BM; Branchi V; Raghav KPS; Maitra A; Guerrero PA; Semaan A
    J Gastrointest Cancer; 2023 Dec; 54(4):1276-1285. PubMed ID: 36862364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary.
    Kato S; Weipert C; Gumas S; Okamura R; Lee S; Sicklick JK; Saam J; Kurzrock R
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34778692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
    Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
    Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.
    Kato S; Krishnamurthy N; Banks KC; De P; Williams K; Williams C; Leyland-Jones B; Lippman SM; Lanman RB; Kurzrock R
    Cancer Res; 2017 Aug; 77(16):4238-4246. PubMed ID: 28642281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
    Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
    J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling.
    Bale TA; Yang SR; Solomon JP; Nafa K; Middha S; Casanova J; Sadowska J; Skakodub A; Ahmad H; Yu HA; Riely GJ; Kris MG; Chandarlapaty S; Rosenblum MK; Gavrilovic I; Karajannis MA; Pentsova E; Miller A; Boire A; Mellinghoff I; Berger MF; Zehir A; Ladanyi M; Benayed R; Arcila ME
    J Mol Diagn; 2021 Jun; 23(6):742-752. PubMed ID: 33781965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches.
    Laprovitera N; Salamon I; Gelsomino F; Porcellini E; Riefolo M; Garonzi M; Tononi P; Valente S; Sabbioni S; Fontana F; Manaresi N; D'Errico A; Pantaleo MA; Ardizzoni A; Ferracin M
    Front Cell Dev Biol; 2021; 9():666156. PubMed ID: 34178989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
    Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of circulating
    Choi J; Cho HY; Jeon J; Kim KA; Han YD; Ahn JB; Wortzel I; Lyden D; Kim HS
    Front Oncol; 2022; 12():1067210. PubMed ID: 36591510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
    Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
    PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Panel Sequencing of DNA Variants in cf-, ev- and tumorDNA for Pancreatic Ductal Adenocarcinoma Patients.
    Waldenmaier M; Schulte L; Schönfelder J; Fürstberger A; Kraus JM; Daiss N; Seibold T; Morawe M; Ettrich TJ; Kestler HA; Kahlert C; Seufferlein T; Eiseler T
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
    Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
    Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: A Chinese pan-cancer cohort.
    Xu E; Su K; Zhou Y; Gong L; Xuan Y; Liao M; Cao J; Li Y; Lu Y; Zhao Y; Chen F
    J Cell Mol Med; 2021 Nov; 25(21):10279-10290. PubMed ID: 34658138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
    Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
    Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 19. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary.
    Conway AM; Pearce SP; Clipson A; Hill SM; Chemi F; Slane-Tan D; Ferdous S; Hossain ASMM; Kamieniecka K; White DJ; Mitchell C; Kerr A; Krebs MG; Brady G; Dive C; Cook N; Rothwell DG
    Nat Commun; 2024 Apr; 15(1):3292. PubMed ID: 38632274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
    Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.